---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-006042"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:08:55.974424+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort

## Summary
- Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.
- First cohort completed in Australian Hemopurifier cancer trial; DSMB approves second cohort with two treatments.
- Amended protocol broadens eligibility to any anti-PD-1 regimen; preclinical data show 98.5% removal of platelet-derived EVs.
- India oncology study dropped due to extended timeline; Long COVID research with UCSF presented at Keystone Symposium.

## SEC filing metadata
- accession: 0001683168-25-006042
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316825006042/0001683168-25-006042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316825006042/aemd_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-006042
- JSON: https://secwatch.observer/filing/0001683168-25-006042.json
- Plain text: https://secwatch.observer/filing/0001683168-25-006042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.